Skip to main content
Erschienen in: Clinical Pharmacokinetics 12/2019

06.06.2019 | Original Research Article

Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children

verfasst von: Fanuel T. Hagos, Christopher M. Horvat, Alicia K. Au, Yvette P. Conley, Lingjue Li, Samuel M. Poloyac, Patrick M. Kochanek, Robert S. B. Clark, Philip E. Empey

Erschienen in: Clinical Pharmacokinetics | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

The objective of this study was to characterize the population pharmacokinetics of fentanyl and identify factors that contribute to exposure variability in critically ill pediatric patients.

Methods

We conducted a single-center, retrospective cohort study using electronic record data and remnant blood samples in the setting of a mixed medical/surgical intensive care unit (ICU) at a quaternary children’s hospital. Children with a predicted ICU length of stay of at least 3 days and presence of an indwelling central venous or arterial line were included. Serum fentanyl measurements were performed for 278 unique remnant samples from 66 patients. Both one- and two-compartment models were evaluated to describe fentanyl disposition. Covariates were introduced into the model in a forward/backward, stepwise approach and included age, sex, race, weight, cytochrome P450 (CYP) 3A5 genotype, and the presence of CYP3A4 or CYP3A5 inducers or inhibitors. Simulations were performed using the successful model to depict the influence of inducers on fentanyl concentrations.

Results

A two-compartment base model best described the data. There was good agreement between observed and predicted concentrations in the final model. The typical fentanyl clearance for 70 kg (reference weight) and 20.1 kg (median weight) patients were 34.6 and 13.6 L/h, respectively. The magnitude of the unexplained random inter-individual variability was high for both clearance (60.7%) and apparent volume of the central compartment (V1) (107.2%). Coadministration of the known CYP3A4/5 inducers fosphenytoin and/or phenobarbital was associated with significantly increased fentanyl clearance. Simulations demonstrate that the effect of inducer administration was most pronounced following discontinuation of a fentanyl infusion.

Conclusions

In this study we show the feasibility and utility of using electronic record data and remnant blood samples to successfully construct population pharmacokinetic models for a heterogeneous cohort of critically ill children. A clinically relevant effect of concomitant CYP3A4/5 inducers was identified. Scaling this population pharmacokinetic approach is necessary to craft precision approaches to fentanyl administration for critically ill children.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Curley MAQ, Wypij D, Watson RS, Grant MJC, Asaro LA, Cheifetz IM, et al. Protocolized sedation vs usual care in pediatric patients mechanically ventilated for acute respiratory failure: a randomized clinical trial. JAMA. 2015;313:379–89.CrossRef Curley MAQ, Wypij D, Watson RS, Grant MJC, Asaro LA, Cheifetz IM, et al. Protocolized sedation vs usual care in pediatric patients mechanically ventilated for acute respiratory failure: a randomized clinical trial. JAMA. 2015;313:379–89.CrossRef
3.
Zurück zum Zitat Ziesenitz VC, Vaughns JD, Koch G, Mikus G, van den Anker JN. Pharmacokinetics of fentanyl and its derivatives in children: a comprehensive review. Clin Pharmacokinet. 2018;57:125–49.CrossRef Ziesenitz VC, Vaughns JD, Koch G, Mikus G, van den Anker JN. Pharmacokinetics of fentanyl and its derivatives in children: a comprehensive review. Clin Pharmacokinet. 2018;57:125–49.CrossRef
4.
Zurück zum Zitat Van Driest SL, Marshall MD, Hachey B, Beck C, Crum K, Owen J, et al. Pragmatic pharmacology: population pharmacokinetic analysis of fentanyl using remnant samples from children after cardiac surgery. Br J Clin Pharmacol. 2016;81:1165–74.CrossRef Van Driest SL, Marshall MD, Hachey B, Beck C, Crum K, Owen J, et al. Pragmatic pharmacology: population pharmacokinetic analysis of fentanyl using remnant samples from children after cardiac surgery. Br J Clin Pharmacol. 2016;81:1165–74.CrossRef
5.
Zurück zum Zitat Peng PWH, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiol J Am Soc Anesthesiol. 1999;90:576–99. Peng PWH, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiol J Am Soc Anesthesiol. 1999;90:576–99.
6.
Zurück zum Zitat Gourlay GK, Kowalski SR, Plummer JL, Cousins MJ, Armstrong PJ. Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. Anesth Analg. 1988;67:329–37.CrossRef Gourlay GK, Kowalski SR, Plummer JL, Cousins MJ, Armstrong PJ. Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. Anesth Analg. 1988;67:329–37.CrossRef
7.
Zurück zum Zitat Katz R, Kelly HW. Pharmacokinetics of continuous infusions of fentanyl in critically ill children. Crit Care Med. 1993;21:995–1000.CrossRef Katz R, Kelly HW. Pharmacokinetics of continuous infusions of fentanyl in critically ill children. Crit Care Med. 1993;21:995–1000.CrossRef
8.
Zurück zum Zitat Frakes MA, Lord WR, Kociszewski C, Wedel SK. Efficacy of fentanyl analgesia for trauma in critical care transport. Am J Emerg Med. 2006;24:286–9.CrossRef Frakes MA, Lord WR, Kociszewski C, Wedel SK. Efficacy of fentanyl analgesia for trauma in critical care transport. Am J Emerg Med. 2006;24:286–9.CrossRef
9.
Zurück zum Zitat Ziesenitz VC, König SK, Mahlke NS, Skopp G, Haefeli WE, Mikus G. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. J Clin Pharmacol. 2015;55:708–17.CrossRef Ziesenitz VC, König SK, Mahlke NS, Skopp G, Haefeli WE, Mikus G. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. J Clin Pharmacol. 2015;55:708–17.CrossRef
10.
Zurück zum Zitat Empey PE, Miller TM, Philbrick AH, Melick JA, Kochanek PM, Poloyac SM. Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest. Crit Care Med. 2012;40:1221–8.CrossRef Empey PE, Miller TM, Philbrick AH, Melick JA, Kochanek PM, Poloyac SM. Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest. Crit Care Med. 2012;40:1221–8.CrossRef
11.
Zurück zum Zitat Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101:72–9.CrossRef Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101:72–9.CrossRef
12.
Zurück zum Zitat Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241–57.CrossRef Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241–57.CrossRef
13.
Zurück zum Zitat Jonsson EN, Karlsson MO. Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51–64.CrossRef Jonsson EN, Karlsson MO. Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51–64.CrossRef
14.
Zurück zum Zitat Choi L, Ferrell BA, Vasilevskis EE, Pandharipande PP, Heltsley R, Ely EW, et al. Population pharmacokinetics of fentanyl in the critically ill. Crit Care Med. 2016;44:64–72.CrossRef Choi L, Ferrell BA, Vasilevskis EE, Pandharipande PP, Heltsley R, Ely EW, et al. Population pharmacokinetics of fentanyl in the critically ill. Crit Care Med. 2016;44:64–72.CrossRef
15.
Zurück zum Zitat Horvat C, Au A, Conley Y, Kochanek P, Li L, Poloyac S, et al. ARDA2A and CYP3A5 genotypes are associated with fentanyl requirements in critically ill children [abstract no. 880]. Crit Care Med. 2018;46:424.CrossRef Horvat C, Au A, Conley Y, Kochanek P, Li L, Poloyac S, et al. ARDA2A and CYP3A5 genotypes are associated with fentanyl requirements in critically ill children [abstract no. 880]. Crit Care Med. 2018;46:424.CrossRef
16.
Zurück zum Zitat Singleton MA, Rosen JI, Fisher DM. Plasma concentrations of fentanyl in infants, children and adults. Can J Anaesth. 1987;34:152–5.CrossRef Singleton MA, Rosen JI, Fisher DM. Plasma concentrations of fentanyl in infants, children and adults. Can J Anaesth. 1987;34:152–5.CrossRef
17.
Zurück zum Zitat Encinas E, Calvo R, Lukas JC, Vozmediano V, Rodriguez M, Suarez E. A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach. Paediatr Drugs. 2013;15:247–57.CrossRef Encinas E, Calvo R, Lukas JC, Vozmediano V, Rodriguez M, Suarez E. A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach. Paediatr Drugs. 2013;15:247–57.CrossRef
18.
Zurück zum Zitat Koehntop DE, Rodman JH, Brundage DM, Hegland MG, Buckley JJ. Pharmacokinetics of fentanyl in neonates. Anesth Analg. 1986;65:227–32.CrossRef Koehntop DE, Rodman JH, Brundage DM, Hegland MG, Buckley JJ. Pharmacokinetics of fentanyl in neonates. Anesth Analg. 1986;65:227–32.CrossRef
19.
Zurück zum Zitat Anderson BJ, Allegaert K. The pharmacology of anaesthetics in the neonate. Best Pract Res Clin Anaesthesiol. 2010;24:419–31.CrossRef Anderson BJ, Allegaert K. The pharmacology of anaesthetics in the neonate. Best Pract Res Clin Anaesthesiol. 2010;24:419–31.CrossRef
20.
Zurück zum Zitat Ariano RE, Duke PC, Sitar DS. Population pharmacokinetics of fentanyl in healthy volunteers. J Clin Pharmacol. 2001;41:757–63.CrossRef Ariano RE, Duke PC, Sitar DS. Population pharmacokinetics of fentanyl in healthy volunteers. J Clin Pharmacol. 2001;41:757–63.CrossRef
21.
Zurück zum Zitat Friis-Hansen B. Body composition during growth. In vivo measurements and biochemical data correlated to differential anatomical growth. Pediatrics. 1971;47(1 Suppl 2):264–72. Friis-Hansen B. Body composition during growth. In vivo measurements and biochemical data correlated to differential anatomical growth. Pediatrics. 1971;47(1 Suppl 2):264–72.
22.
Zurück zum Zitat Weber DR, Leonard MB, Zemel BS. Body composition analysis in the pediatric population. Pediatr Endocrinol Rev PER. 2012;10:130–9.PubMed Weber DR, Leonard MB, Zemel BS. Body composition analysis in the pediatric population. Pediatr Endocrinol Rev PER. 2012;10:130–9.PubMed
23.
Zurück zum Zitat Mulla H, Johnson TN. Dosing dilemmas in obese children. Arch Dis Child Educ Pract Ed. 2010;95:112–7.CrossRef Mulla H, Johnson TN. Dosing dilemmas in obese children. Arch Dis Child Educ Pract Ed. 2010;95:112–7.CrossRef
24.
Zurück zum Zitat Bower S, Hull CJ. Comparative pharmacokinetics of fentanyl and alfentanil. Br J Anaesth. 1982;54:871–7.CrossRef Bower S, Hull CJ. Comparative pharmacokinetics of fentanyl and alfentanil. Br J Anaesth. 1982;54:871–7.CrossRef
25.
Zurück zum Zitat Ibrahim AE, Feldman J, Karim A, Kharasch ED. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 2003;98:853–61.CrossRef Ibrahim AE, Feldman J, Karim A, Kharasch ED. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 2003;98:853–61.CrossRef
26.
Zurück zum Zitat Kuip EJM, Zandvliet ML, Koolen SLW, Mathijssen RHJ, van der Rijt CCD. A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients. Br J Clin Pharmacol. 2017;83:294–313.CrossRef Kuip EJM, Zandvliet ML, Koolen SLW, Mathijssen RHJ, van der Rijt CCD. A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients. Br J Clin Pharmacol. 2017;83:294–313.CrossRef
27.
Zurück zum Zitat Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos Biol Fate Chem. 1996;24:932–9.PubMed Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos Biol Fate Chem. 1996;24:932–9.PubMed
28.
Zurück zum Zitat Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg. 1996;82:167–72.PubMed Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg. 1996;82:167–72.PubMed
29.
Zurück zum Zitat Takashina Y, Naito T, Mino Y, Yagi T, Ohnishi K, Kawakami J. Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet. 2012;27:414–21.CrossRef Takashina Y, Naito T, Mino Y, Yagi T, Ohnishi K, Kawakami J. Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet. 2012;27:414–21.CrossRef
30.
Zurück zum Zitat Zhou S-F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9:310–22.CrossRef Zhou S-F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9:310–22.CrossRef
31.
Zurück zum Zitat Hukkanen J. Induction of cytochrome P450 enzymes: a view on human in vivo findings. Expert Rev Clin Pharmacol. 2012;5:569–85.CrossRef Hukkanen J. Induction of cytochrome P450 enzymes: a view on human in vivo findings. Expert Rev Clin Pharmacol. 2012;5:569–85.CrossRef
32.
Zurück zum Zitat Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmöller J, et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem. 2004;279:38379–85.CrossRef Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmöller J, et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem. 2004;279:38379–85.CrossRef
33.
Zurück zum Zitat Wortham M, Czerwinski M, He L, Parkinson A, Wan Y-JY. Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos Biol Fate Chem. 2007;35:1700–10.CrossRef Wortham M, Czerwinski M, He L, Parkinson A, Wan Y-JY. Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos Biol Fate Chem. 2007;35:1700–10.CrossRef
34.
Zurück zum Zitat Landay RA, Gonzalez MA, Taylor JC. Effect of phenobarbital on theophylline disposition. J Allergy Clin Immunol. 1978;62:27–9.CrossRef Landay RA, Gonzalez MA, Taylor JC. Effect of phenobarbital on theophylline disposition. J Allergy Clin Immunol. 1978;62:27–9.CrossRef
35.
Zurück zum Zitat Dahlqvist R, Steiner E, Koike Y, von Bahr C, Lind M, Billing B. Induction of theophylline metabolism by pentobarbital. Ther Drug Monit. 1989;11:408–10.CrossRef Dahlqvist R, Steiner E, Koike Y, von Bahr C, Lind M, Billing B. Induction of theophylline metabolism by pentobarbital. Ther Drug Monit. 1989;11:408–10.CrossRef
36.
Zurück zum Zitat Wietholtz H, Zysset T, Kreiten K, Kohl D, Büchsel R, Matern S. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol. 1989;36:401–6.CrossRef Wietholtz H, Zysset T, Kreiten K, Kohl D, Büchsel R, Matern S. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol. 1989;36:401–6.CrossRef
37.
Zurück zum Zitat Miller M, Cosgriff J, Kwong T, Morken DA. Influence of phenytoin on theophylline clearance. Clin Pharmacol Ther. 1984;35:666–9.CrossRef Miller M, Cosgriff J, Kwong T, Morken DA. Influence of phenytoin on theophylline clearance. Clin Pharmacol Ther. 1984;35:666–9.CrossRef
38.
Zurück zum Zitat Ohnhaus EE, Breckenridge AM, Park BK. Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol. 1989;36:39–46.CrossRef Ohnhaus EE, Breckenridge AM, Park BK. Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol. 1989;36:39–46.CrossRef
39.
Zurück zum Zitat Olsen L, Aisner D, McGinnis JM, Institute of Medicine (U.S.), editors. The learning healthcare system: workshop summary. Washington, DC: National Academies Press; 2007. Olsen L, Aisner D, McGinnis JM, Institute of Medicine (U.S.), editors. The learning healthcare system: workshop summary. Washington, DC: National Academies Press; 2007.
40.
Zurück zum Zitat Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54:11–27.CrossRef Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54:11–27.CrossRef
41.
Zurück zum Zitat Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, et al. Rifampin’s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011;89:234–42.CrossRef Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, et al. Rifampin’s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011;89:234–42.CrossRef
Metadaten
Titel
Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children
verfasst von
Fanuel T. Hagos
Christopher M. Horvat
Alicia K. Au
Yvette P. Conley
Lingjue Li
Samuel M. Poloyac
Patrick M. Kochanek
Robert S. B. Clark
Philip E. Empey
Publikationsdatum
06.06.2019
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 12/2019
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-019-00773-1

Weitere Artikel der Ausgabe 12/2019

Clinical Pharmacokinetics 12/2019 Zur Ausgabe